Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

AstraZeneca logo

AstraZeneca

Status and phase

Active, not recruiting
Phase 3

Conditions

Endometrial Neoplasms

Treatments

Biological: durvalumab
Drug: olaparib
Drug: Paclitaxel
Drug: durvalumab placebo
Drug: olaparib placebo
Drug: Carboplatin

Study type

Interventional

Funder types

Industry
Other

Identifiers

NCT04269200
D9311C00001 (Other Identifier)
2019-004112-60 (EudraCT Number)
ENGOT-EN10 (Other Identifier)
GOG-3041 (Other Identifier)

Details and patient eligibility

About

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

Full description

This Phase III study will assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer. Target patient population: Adult female patients with histologically confirmed diagnosis of epithelial endometrial carcinoma (excluding sarcomas): newly diagnosed Stage III, newly diagnosed Stage IV, or recurrent endometrial cancer

Enrollment

805 patients

Sex

Female

Ages

18 to 150 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years at the time of screening and female.
  • Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies, including carcinosarcomas, will be allowed. Sarcomas will not be allowed.

Patient must have endometrial cancer in one of the following categories:

  • Newly diagnosed Stage III disease (measurable disease per RECIST 1.1 following surgery or diagnostic biopsy),
  • Newly diagnosed Stage IV disease (with or without disease following surgery or diagnostic biopsy)
  • Recurrence of disease (measurable or non-measurable disease per RECIST 1.1) where the potential for cure by surgery alone or in combination is poor.
  • Naïve to first line systemic anti-cancer treatment. For patients with recurrent disease only, prior systemic anti-cancer treatment is allowed only if it was administered in the adjuvant setting and there is at least 12 months from date of last dose of systemic anti-cancer treatment administered to date of subsequent relapse
  • FPPE tumor sample must be available for MMR evaluation.
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days of starting study treatment.

Exclusion criteria

  • History of leptomeningeal carcinomatosis.
  • Brain metastases or spinal cord compression.
  • Prior treatment with PARP inhibitors.
  • Any prior exposure to immune-mediated therapy, including (but not limited to) other anti CTLA-4, anti-PD-1, anti-PD-L1, or anti-programmed-cell-death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

805 participants in 3 patient groups

Arm A (control)
Active Comparator group
Description:
Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
Treatment:
Drug: Carboplatin
Drug: olaparib placebo
Drug: Paclitaxel
Drug: durvalumab placebo
Arm B (durvalumab+placebo)
Experimental group
Description:
Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
Treatment:
Drug: Carboplatin
Drug: olaparib placebo
Drug: Paclitaxel
Biological: durvalumab
Arm C (durvalumab+olaparib)
Experimental group
Description:
Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
Treatment:
Drug: Carboplatin
Drug: Paclitaxel
Drug: olaparib
Biological: durvalumab

Trial contacts and locations

203

Loading...

Central trial contact

AstraZeneca Clinical Study Information Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems